Effect and Mechanism of Early Intervention with Liraglutide to Improve the Kidney Injuries in Rats with Glycometabolism Disorder
Jin Chen,Yifeng Xu,Lu Yang,Jinbo Chen,Junhao Xie,Changhua Ding,Qin Huang
2019-01-01
Latin american journal of pharmacy
Abstract:Liraglutide is a kind of GLP-1 receptor agonists. Here we investigated whether the early intervention with liraglutide can improve the kidney injuries in rats with glycometabolism disorder and explored its possible mechanism. The animal models of SD rats with impaired glucose tolerance (IGT) or type 2 diabetes (T2DM) were induced with 10mg/kg or 20mg/kg streptozocin (STZ) by intraperitoneal injection after 8 weeks high-fat diet (HFD). The rats were randomly divided into the normal control group, IGT control group, IGT group treated by liraglutide, T2DM control group, T2DM group treated by liraglutide and T2DM group treated by insulin. After five weeks intervention, blood lipid, renal function, cystatin C, urine albumin creatinine ratio (UACR), blood glucose(BG) and islet function by OGTT were tested. The morphological changes of renal tissues were observed by light microscopy with HE staining and electron microscopy. The expression levels of TGF, CTGF and VEGF in renal tissues were detected by immunohistochemistry. The protein expression of mTOR and P70S6k was detected by Western Blot. The mRNA expression of mTOR, CTGF, VEGF, NOX-4 in renal tissues was detected by qRT-PCR. compared with the IGT and diabetes control group, the blood glucose(BG), total cholesterol(TC) and triglyceride(TG) levels were significantly reduced in the treatment group with liraglutide (all p<0.05). BG of the diabetes group treated by liraglutide was similar to that by insulin, and UACR was lower than the diabetes control group. The hypertrophy of glomeruli and the proliferation of mesangial cells was significantly improved, and the number of podocytes increased significantly after liraglutide treatment. The expression levels of TGF-beta 1, CTGF and VEGF were significantly decreased in the renal tissues of liraglutide treatment group compared with those in the control group and insulin treatment group by immunohistochemistry. Compared with those in the insulin treatment group, the protein levels of p-mTOR and pp70S6k and the mRNA levels of CTGF, VEGF and NOX-4 of the renal tissues were significantly decreased in the liraglutide treatment group. Early intervention with liraglutide could improve renal injuries in IGT and T2DM rats. Liraglutide treatment might inhibit mTOR pathway, reduce p-mTOR levels, improve the mTOR signaling pathways, reduce inflammatory cytokines, thus alleviate glomerular sclerosis, improve the morphology and quantity of podocytes, reduce urinary albumin further, and delay the progress of kidney disease.